Cargando…

Correction: Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials

Detalles Bibliográficos
Autores principales:	Liu, Yao, Zhang, Song, Li, Dao-wei, Jiang, Shu-juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692717/ http://dx.doi.org/10.1371/annotation/8da4be4b-2de1-4c51-9c40-0f49dc212579

Ejemplares similares

Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Liu, Yao, et al.
Publicado: (2013)

Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich’s Syndrome
por: Matucci, Andrea, et al.
Publicado: (2018)

Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion
por: Tello, Khodr, et al.
Publicado: (2019)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

May mepolizumab used in asthma correct subfertility?
por: Ozden, Guzin, et al.
Publicado: (2021)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
por: Domingo Ribas , Christian, et al.
Publicado: (2021)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
por: Roufosse, Florence, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects
por: Tsukamoto, Naohiro, et al.
Publicado: (2015)

Severe Pediatric Asthma Therapy: Mepolizumab
por: Ullmann, Nicola, et al.
Publicado: (2022)

Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis
por: Henriksen, Daniel P., et al.
Publicado: (2018)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
por: Menzella, Francesco, et al.
Publicado: (2015)

Higher Binding Affinity and In Vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab
por: Liddament, Mark, et al.
Publicado: (2018)

Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]
Publicado: (2021)

Characteristics of new adult users of mepolizumab with asthma in the USA
por: Wu, Ann Chen, et al.
Publicado: (2021)

Daily Physical Activity in Asthma and the Effect of Mepolizumab Therapy
por: Panagiotou, Marios, et al.
Publicado: (2022)

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma
por: Domingo, Christian, et al.
Publicado: (2023)

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
por: Prætorius, Katrine, et al.
Publicado: (2021)

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
por: Charles, David, et al.
Publicado: (2022)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
por: Kim, Mi-Kyeong, et al.
Publicado: (2021)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Mepolizumab does not alter the blood basophil count in severe asthma
por: Wright, Adam Kelvin Alec, et al.
Publicado: (2019)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
por: Karim, Azmat, et al.
Publicado: (2022)

Correction: Asthma and the risk of lung cancer: a meta-analysis
por: Qu, Yan-Liang, et al.
Publicado: (2017)

Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis
por: Wang, Fa-Ping, et al.
Publicado: (2016)

Correction: Short-Term Efficacy of Rofecoxib and Diclofenac in Acute Shoulder Pain: A Placebo-Controlled Randomized Trial
Publicado: (2007)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance
por: Miyokawa, Reika, et al.
Publicado: (2020)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Outcomes over the first two years of treatment with mepolizumab in severe asthma
por: Elsey, Lynn, et al.
Publicado: (2021)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
por: Gibson, Peter G., et al.
Publicado: (2021)

Correction: Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial
por: Duval, Xavier, et al.
Publicado: (2010)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
por: Bagnasco, Diego, et al.
Publicado: (2023)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ug1ti9pdlflbnq0td4v6tq9chp